Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 89 of 89

TitleReference numberPublishedLast updated
Non-indicator text resourceCG1027
Test Syndication - IFPNG295
MLB test IFP resource for syndicationNG296
HTE temp withdrawnHST120
Temp Withdrawn TestCG203
Master test-639NG243
Claire testCG8923
PUB602 pretestNG242
Master new feeds testCG273
NG Pdf testNG275
Test Product 554DG65
Test Product 554CG272
DG test -636DG92
Test PUB636CG200
PUB550 testCG279
PUB550 testCG197
DG Content Order testDG95
Content Order testCG199
Master test-552DG91
PUB-552 testDG90
Master Pub testCG195
Conversion word testCG194
PUB-545 Resource Type testDG59
Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgusIPG789
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Image-guided percutaneous laser ablation for primary and secondary liver tumoursIPG788
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesIPG787
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liverIPG786
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Atogepant for preventing migraineTA973
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
COVID-19 rapid guideline: managing COVID-19NG191
Artificial intelligence (AI)-derived software to help clinical decision making in strokeDG57
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTE18
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Endometriosis: diagnosis and managementNG73
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Twin and triplet pregnancyNG137
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
GaitSmart rehabilitation exercise programme for gait and mobility issuesMTG78
Kurin Lock for blood culture collectionMTG77
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Desflurane for maintenance of anaesthesiaES41
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTE17
Ovarian cancer: identifying and managing familial and genetic riskNG241
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Neonatal infection: antibiotics for prevention and treatmentNG195
Suspected sepsis: recognition, diagnosis and early managementNG51
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and managementNG240
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTE5
Dupilumab for treating moderate to severe prurigo nodularisTA955
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTE14
Digital technologies for managing non-specific low back pain: early value assessmentHTE16

Results per page

  1. 10
  2. 25
  3. 50
  4. All